SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $249,579 | -46.1% | 12,129 | +23.3% | 0.00% | -100.0% |
| Q2 2023 | $462,640 | -17.5% | 9,840 | -26.3% | 0.00% | 0.0% |
| Q1 2023 | $560,543 | +6.2% | 13,360 | -3.3% | 0.00% | 0.0% |
| Q4 2022 | $528,000 | -1.5% | 13,823 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $536,000 | +19.9% | 13,673 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $447,000 | +18.3% | 13,814 | +21.1% | 0.00% | 0.0% |
| Q1 2022 | $378,000 | +27.7% | 11,406 | +63.6% | 0.00% | 0.0% |
| Q4 2021 | $296,000 | +166.7% | 6,974 | +175.7% | 0.00% | – |
| Q3 2021 | $111,000 | -78.9% | 2,530 | -72.5% | 0.00% | -100.0% |
| Q2 2021 | $527,000 | +621.9% | 9,211 | +852.5% | 0.00% | – |
| Q1 2021 | $73,000 | -26.3% | 967 | -15.2% | 0.00% | – |
| Q4 2020 | $99,000 | +219.4% | 1,141 | +121.1% | 0.00% | – |
| Q3 2020 | $31,000 | -3.1% | 516 | -35.3% | 0.00% | – |
| Q2 2020 | $32,000 | +28.0% | 798 | -10.6% | 0.00% | – |
| Q1 2020 | $25,000 | – | 893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
| Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
| Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
| DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
| Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
| Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
| Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
| Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
| Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
| SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |